iiinova — where your digital self keeps evolving

Daniel Fuster @danfuster.bsky.social · 17/06/2025

Thank you Swiss National Science Foundation !! We just received 3.42 Mio CHF funding for our EMPASTONE trial. Looking forward to working with colleagues in Switzerland, Germany, France, Italy and the UK. clinicaltrials.gov/study/NCT066...

clinicaltrials.gov

ClinicalTrials.gov

260

Reposted by Daniel Fuster

markusathome @markusathome.bsky.social · 11/04/2025

Our new webinar in german language: SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz) WATCH NOW: youtu.be/i_YTcIQ4YQk?... @danfuster.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social

youtu.be

SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz)

YouTube video by MARKUS at HOMe

074

Daniel Fuster @danfuster.bsky.social · 29/03/2025

Thank you Pedro. Unfortunately not many groups working on these important transporters anymore.

020

Reposted by Daniel Fuster

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 19/03/2025

So @danfuster.bsky.social and colleagues seem to find HCTZ doesn’t work for anything! In a post hoc analysis of NOSTONE (where CT scans were done in all & repurposed for calculating bone density) HCTZ doesn’t increase it vs placebo journals.lww.com/cjasn/pages/... in @asnpublications.bsky.social

visual abstract of NOSTONE and bone density from Hector

165

Reposted by Daniel Fuster

markusathome @markusathome.bsky.social · 12/03/2025

Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney Stones: A Post Hoc Analysis of the NOSTONE Trial by Drs. Christe, @danfuster.bsky.social et al. journals.lww.com/cjasn/abstra... HCTZ up to 50 mg daily did not preserve BMD compared to placebo over 3 years!

031

Reposted by Daniel Fuster

Pedro H. Imenez Silva @imenezpedro.bsky.social · 04/03/2025

Happy to share that our research letter has been accepted in @ndt-era.bsky.social. Here we showed that impaired renal acid excretion is strongly associated with CaOx stone presence in the Swiss Kidney Stone Cohort: bit.ly/41rKodu. Many thanks to all co-authors in Switzerland for their support.

bit.ly

Acid excretion is impaired in calcium oxalate stone formers

Pedro H Imenez Silva, Nasser A Dhayat, Daniel G Fuster, Harald Seeger, Alexander Ritter, Thomas Ernandez, Florian Buchkremer, Beat Roth, Olivier Bonny, Isa

063

Daniel Fuster @danfuster.bsky.social · 15/12/2024

Agree. This study shows nicely that it is dose equivalence and not type of thiazide that matters. CTD is ~2x more potent than HCT (and Indapamide ~20x more potent than HCT).

000

Daniel Fuster @danfuster.bsky.social · 11/12/2024

Not that I know of - and yes this should be done. Likely indirect effect in PT (as is the case for SGLT2i-mediated inhibition of NHE3), yet direct inhibition cannot be ruled out at this stage. NaDC1 has been a prime target for stone prevention for long-it seems SGLT2is are what we were looking for !

020

Daniel Fuster @danfuster.bsky.social · 09/12/2024

No - we were told first two weeks in January 25

000

Daniel Fuster @danfuster.bsky.social · 09/12/2024

Many putative mechanisms how RSR CaP can affect CaOx stone formation (Randall, heterogeneous nucleation etc), but also threats ( increase in urine calcium). This is why we need outcome data

121

Daniel Fuster @danfuster.bsky.social · 09/12/2024

Went up slightly from 30 to 35 mmol/d.

011

Daniel Fuster @danfuster.bsky.social · 09/12/2024

SGLT2is likely inhibit citrate reabsorption in the PT. No need for alkalosis. Urine citrate and pH drove reduction in RSR CaP. Urine calcium went up in patients with calcium stones, no change in oxalate.

131

Reposted by Daniel Fuster

Florian Buchkremer @swissnephro.bsky.social · 07/12/2024

… and you might even dream (or fool yourself?) about achieving lower sodium intake in your patients, but the most likely explanation for the negative result of #NOSTONE, is just that: Thiazides do not work very well in preventing recurrent kidney stones. 2/2

021

Reposted by Daniel Fuster

Florian Buchkremer @swissnephro.bsky.social · 07/12/2024

I’m biased (local PI, steering committee), but the quality of #NOSTONE far exceeds most (if not all) data that the critics base their many assumptions and beliefs on. You can speculate about the additional effects of citrate or a different type or dose of diuretic, … 1/2

121

Daniel Fuster @danfuster.bsky.social · 21/11/2024

Acidosis and CKD journals.lww.com/cjasn/citati... "Whether there will be a definitive, adequately powered trial of this inexpensive, fairly safe intervention in CKD is up to funding agencies to decide" Cardiology is doing large outcome trials with colchicine - why can we not do this with alkali ?

journals.lww.com

1102